Press release

Vimian Group acquires product portfolios of veterinary surgical instruments and orthopedic implants

Vimian Group has acquired two product portfolios of veterinary surgical instruments and orthopedic implants in the US. The acquisition marks the entry into a new product category with veterinary surgical instrumentation and expands Vimian’s portfolio of high-quality orthopedic implants for companion animals. The acquired portfolios have combined annual revenues of around USD 6.5 million.

Vimian Group’s MedTech segment, Movora, has acquired two product portfolios of veterinary surgical instruments and orthopedic implants sold to veterinary clinics across North America under the brands Spectrum and Everost. The acquisition is a carve-out from a healthcare company. The acquired portfolios include a wide range of high-quality veterinary orthopedic implants sold under the brand Everost as well as a broad offering of surgical instruments developed specifically for veterinary applications and sold under the brand Spectrum.

“This acquisition marks our entry into a new product category with veterinary surgical instrumentation and expands our portfolio of high-quality orthopedic implants. We gain access to a loyal customer base that we can leverage for our entire MedTech offering in the US and foresee significant synergy potential as we integrate these product portfolios into our commercial infrastructure around the world”, says Patrick Gendreau, Co-CEO of Vimian’s MedTech segment Movora.

The acquisition has a marginal impact on Vimian’s earnings per share and was consolidated into Vimian’s MedTech segment on 4 April, 2022.

About Vimian

Vimian is a global, fast-growing group of innovation-driven companies with a shared passion for making a positive impact through improving animal health. Together, we put science, technology and our customers’ needs at the centre of everything we do to deliver effective solutions to veterinary professionals, labs and pet parents around the world. We bring together pioneering and entrepreneurial businesses in animal health, with an aim to create a uniquely diversified proposition of products and services of the highest standard. Our group covers four essential and rapidly evolving areas within animal health: Specialty Pharma, Diagnostics, Veterinary Services and MedTech. Vimian provides individual businesses with access to our networks, expertise, infrastructure and capital to accelerate innovation and growth. We are as passionate about supporting leadership within our existing businesses, as we are about welcoming new partners to the Vimian family – together helping us make an even greater impact by improving animal health. Headquartered in Stockholm, Sweden, Vimian and our family of companies reach over 15,000 customers in +150 markets, employ more than 600 people and have a combined annual turnover of approximately EUR 170 million. FNCA Sweden AB is appointed the Company’s Certified Adviser, info@fnca.se, +46 (0) 8-528 00 399. For more information, please visit: www.vimian.com.